Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · Real-Time Price · USD
17.03
0.00 (0.00%)
Aug 26, 2026, 4:00 PM EDT - Market closed
Theravance Biopharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 104.31 | 107.46 | 64.38 | 57.42 | 51.35 | 55.31 | |
Revenue Growth | 35.11% | 66.92% | 12.12% | 11.84% | -7.17% | -23.03% |
Cost of Revenue | 26.01 | 37.41 | 37.64 | 40.62 | 63.39 | 193.66 |
Gross Profit | 78.3 | 70.05 | 26.74 | 16.8 | -12.05 | -138.35 |
Selling, General & Admin | 68.75 | 73.65 | 69.17 | 70.1 | 67.07 | 99.3 |
Operating Expenses | 68.75 | 73.65 | 69.17 | 70.45 | 67.07 | 99.3 |
Operating Income | 9.55 | -3.6 | -42.44 | -53.65 | -79.12 | -237.64 |
Interest Expense | -1.16 | -2.46 | -2.55 | -2.35 | -6.37 | -8.55 |
Interest & Investment Income | 14.38 | 10.27 | 4.98 | 9.02 | 6.74 | 2.01 |
Currency Exchange Gain (Loss) | -0.1 | -0.1 | -0.1 | 0.1 | -0.9 | -0.9 |
Other Non Operating Income (Expenses) | -75.14 | - | - | - | - | - |
EBT Excluding Unusual Items | -52.47 | 4.11 | -40.1 | -46.88 | -79.65 | -245.08 |
Merger & Restructuring Charges | -7.66 | - | - | -2.39 | -12.84 | -20.14 |
Gain (Loss) on Sale of Assets | - | - | - | - | 2.71 | - |
Asset Writedown | - | - | -4.51 | - | - | - |
Other Unusual Items | 119.05 | 125.14 | - | - | -3.03 | - |
Pretax Income | 58.92 | 129.25 | -44.61 | -49.27 | -92.82 | -265.22 |
Income Tax Expense | 5.11 | 23.35 | 11.8 | 5.92 | 0.01 | -0.15 |
Earnings From Continuing Operations | 53.81 | 105.9 | -56.42 | -55.19 | -92.82 | -265.07 |
Earnings From Discontinued Operations | - | - | - | - | 964.96 | 65.65 |
Net Income | 53.81 | 105.9 | -56.42 | -55.19 | 872.13 | -199.43 |
Net Income to Common | 53.81 | 105.9 | -56.42 | -55.19 | 872.13 | -199.43 |
Net Income Growth | 312.92% | - | - | - | - | - |
Shares Outstanding (Basic) | 51 | 50 | 49 | 55 | 74 | 69 |
Shares Outstanding (Diluted) | 52 | 52 | 49 | 55 | 74 | 69 |
Shares Change | 3.94% | 5.45% | -11.67% | -24.85% | 5.95% | 11.41% |
EPS (Basic) | 1.05 | 2.10 | -1.15 | -1.00 | 11.85 | -2.87 |
EPS (Diluted) | 1.05 | 2.06 | -1.15 | -1.00 | 11.85 | -2.87 |
EPS Growth | 300.80% | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 53.73 | 238.5 | -11.87 | -29.49 | -187.56 | -211.26 |
Free Cash Flow Per Share | 1.03 | 4.63 | -0.24 | -0.53 | -2.55 | -3.04 |
Gross Margin | 75.06% | 65.19% | 41.53% | 29.26% | -23.46% | -250.12% |
Operating Margin | 9.16% | -3.35% | -65.91% | -93.43% | -154.09% | -429.65% |
Profit Margin | 51.58% | 98.54% | -87.63% | -96.11% | 1698.54% | -360.55% |
Free Cash Flow Margin | 51.51% | 221.93% | -18.43% | -51.35% | -365.29% | -381.96% |
EBITDA | 11.1 | -1.98 | -40.73 | -51.65 | -76.08 | -232.83 |
EBITDA Margin | 10.64% | -1.84% | -63.26% | -89.94% | -148.18% | - |
D&A For EBITDA | 1.55 | 1.63 | 1.71 | 2 | 3.04 | 4.81 |
EBIT | 9.55 | -3.6 | -42.44 | -53.65 | -79.12 | -237.64 |
EBIT Margin | 9.16% | -3.35% | -65.91% | -93.43% | -154.09% | - |
Effective Tax Rate | 8.67% | 18.07% | - | - | - | - |
Revenue as Reported | 104.31 | 107.46 | 64.38 | 57.42 | 51.35 | 55.31 |
Advertising Expenses | - | 5.1 | 4.3 | 5.1 | 8 | 9.3 |